Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Acral Malignant Melanoma

Exclusion criteria

• . Prior therapy with VEGFR-target TKI included anlotinib or an anti-programmed cell death (PD)-1, anti-PD-L1, anti-PD-L2, anti-tumor necrosis factor CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody ,or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
• . Hypersensitivity to recombinant humanized anti-PD-1 monoclonal Abm or its components.
• . Has diagnosed and/or treated additional malignancy within 5 years prior to randomization. Exceptions include cured basal cell carcinoma of skin and carcinoma in situ of cervix.
• . Has any active autoimmune disease or history of autoimmune disease.
• . Immunosuppressive therapy with immunosuppressive agents or systemic or absorbable local hormones (dosage \> 10 mg/day prednisone or other therapeutic hormones) is required for the purpose of immunosuppression, and is still in use for 2 weeks after the first administration.
• . Has multiple factors affecting oral medication.
• . Has uncontrollable pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures.
• . Has any bleeding or bleeding events ≥ grade 3 or with unhealed wounds, ulcerative , or fractures within 4 weeks prior to the first administration.